Quantcast

Latest Array BioPharma Inc. Stories

2014-05-13 23:15:05

Corridor Company, a leader in contract management and business-critical applications for SharePoint, is pleased to announce that Array BioPharma has selected Corridor’s Contract Management Business App for SharePoint – CM[.app]™ – as its contract lifecycle management tool. Wakefield, MA (PRWEB) May 13, 2014 Corridor Company, a leader in contract management and business-critical applications for SharePoint, is pleased to announce that Array BioPharma has selected Corridor’s...

2014-05-12 12:31:16

BOULDER, Colo., May 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare Conference in New York City. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO...

2014-04-29 08:35:40

Binimetinib Continues to Advance in Clinical Development BOULDER, Colo., April 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the third quarter of its fiscal year ending June 30, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Revenue for the third quarter of fiscal 2014 was $7.8 million, compared to $10.0 million for the same period last year. Revenue decreased due to reduction in recognition of license and milestone payments from our...

2014-04-28 16:31:03

Industry veteran brings additional oncology drug development experience BOULDER, Colo., April 28, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Dr....

2014-04-23 20:23:20

BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Conference Call Information Date: Tuesday, April...

2014-04-23 12:31:04

Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian Cancer BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib...

2014-03-03 08:31:20

6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) reported full results from a randomized Phase 2 trial of ARRY-502 in patients with mild to moderate Th2-Driven Asthma at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO ARRY-502, an oral CRTh2 antagonist, was studied in a...

2014-02-20 08:32:05

SEATTLE, WA and BOULDER, CO, Feb. 20, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array....

2014-02-18 12:31:10

BOULDER, Colo., Feb. 18, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the RBC Capital Markets Global Healthcare and Cowen Annual Healthcare Conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Event: RBC Capital Markets Global Healthcare Conference...

2014-02-06 16:28:04

BOULDER, Colo., Feb. 6, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Event: Leerink Swann Healthcare Conference Presenter: Ron Squarer, Chief Executive...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.